Add BrightSurf on Google Email

Highly-stabilized and selective inhibitor for cancer-causing enzyme revealed

Researchers at the Hebrew University of Jerusalem have developed a highly selective inhibitor for Matrix Metallopeptidase 7 (MMP7), an enzyme crucial for cancer spread and progression. The novel peptide D'20 demonstrates remarkable stability and selectivity, targeting MMP7 while leaving similar enzymes unaffected.

SourceThe Hebrew University of Jerusalem·JournalAngewandte Chemie·TypeExperimental study·DateOct 15, 2024

Tumor evolution is written in the genome

A research team at IIT has identified a molecular signature in triple-negative breast cancer cells that can predict the formation of metastases and chemotherapy resistance. The study used single-cell sequencing to track the evolution of cancer cells over time, revealing key epigenetic features involved in tumor development.

SourceIstituto Italiano di Tecnologia - IIT·JournalNature Communications·TypeExperimental study·DateOct 14, 2024

CNIO researchers propose a new treatment for brain metastasis based on immunotherapy

Researchers at CNIO propose a new treatment for brain metastasis by targeting pro-tumour astrocytes with immunotherapy. They identified TIMP1 as a biomarker to predict when immunotherapy is effective, and a clinical trial is underway to test the therapeutic efficacy of silibinin inhibition.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalCancer Discovery·TypeExperimental study·DateOct 2, 2024

How does cancer spread? Follow the map

Researchers at Cold Spring Harbor Laboratory create a roadmap of how prostate cancer spreads throughout the body, showing that aggressive cells seed cancer's rare migrations to bones, liver, lungs, and lymph nodes. The new technology offers a clearer picture of cancer spread and could lead to more targeted therapeutics.

SourceCold Spring Harbor Laboratory·JournalCancer Discovery·DateSep 25, 2024

Scientists discover how the body's killer cells attack cancer

Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.

SourceUniversity of Southampton·JournalScience Advances·TypeRandomized controlled/clinical trial·DateAug 28, 2024

Promising treatment for rectal cancer confirmed in major study

A new treatment approach has been confirmed effective in a major study, showing that locally advanced rectal cancer patients can experience complete tumour disappearance without needing surgery. This method reduces the risk of recurrence and preserves normal bowel function, offering a promising alternative to traditional treatments.

SourceUppsala University·JournalEClinicalMedicine·TypeObservational study·DateAug 22, 2024

Precision therapy for metastatic prostate cancer improves survival

A new study published in Nature Medicine shows that precision therapy can improve survival for men with metastatic castration-resistant prostate cancer. The treatment, which involves analyzing the genetic profile of the tumor, has been shown to be more effective than chemotherapy in patients whose tumors have specific mutations.

SourceKarolinska Institutet·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateAug 20, 2024

Drug shows promise for treating brain tumors resulting from breast cancer, UT Health San Antonio trial reports

A trial at UT Health San Antonio found that Sacituzumab Govitecan was well-tolerated and showed signs of effectiveness for patients with breast cancer who had progressed to brain tumors. The drug has been shown to deliver a topoisomerase inhibitor into tumors, providing promising clinical signals of efficacy.

SourceUniversity of Texas Health Science Center at San Antonio·JournalNature Communications·TypeRandomized controlled/clinical trial·DateAug 8, 2024

Dealing with runaway metastatic disease

Researchers discuss how PROM2 is a predictive biomarker of distant metastases and shorter survival among patients with stage III melanomas. They also demonstrate that runaway metastasis is closely linked to PROM2 overexpression, through increased epithelial-to-mesenchymal transition marker expression and ferroptosis resistance.

SourceImpact Journals LLC·JournalOncotarget·TypeCommentary/editorial·DateAug 7, 2024

Preventing cancer cells from colonizing the liver

Cancer cells can attach themselves to liver cells when specific proteins are present, allowing them to colonize and form new tumors. This discovery provides insights into the metastatic process and may lead to potential treatments that prevent cancer from establishing new tumors.

SourceETH Zurich·JournalNature·TypeExperimental study·DateJul 24, 2024

Key driver for epithelial cancer development identified

A distinct TNF-α signaling program has been identified as a key driver of epithelial cancer development, contributing to cell proliferation and invasion. The researchers found that this program is active in both normal tissues and tumors, but its level of activity correlates with tumor aggressiveness.

SourceUniversity of Zurich·JournalNature·TypeExperimental study·DateJul 17, 2024

Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer

Researchers from Radboud University Medical Center discuss the potential of using early on-treatment circulating tumor DNA measurements as a response assessment for metastatic castration-resistant prostate cancer. The detection of ctDNA at baseline and 4-weeks after treatment initiation can predict response durability to first-line ARPIs.

SourceImpact Journals LLC·JournalOncotarget·TypeExperimental study·DateJul 17, 2024

RNAs may help identify stage II colon cancer patients who may benefit from chemotherapy following surgery

A new study has identified specific RNAs that may help identify stage II colon cancer patients who are likely to benefit from chemotherapy following surgery. The researchers found that certain housekeeping RNAs were up-regulated in patients with recurrence, suggesting their potential role in the metastatic process.

SourceElsevier·JournalAmerican Journal Of Pathology·TypeExperimental study·DateJul 8, 2024

Novel blood test helps improve cancer treatments

A new liquid biopsy method analyzes gene fragments in the bloodstream to detect and track cancer, enabling oncologists to tailor treatment approaches to individual patients. This non-invasive test can help monitor treatment success, detect cancer recurrence, and improve patient quality of life.

SourceUniversity of Zurich·JournalRadiotherapy and Oncology·TypeExperimental study·DateJul 1, 2024

Study identifies potential pathway to reducing breast cancer brain metastases

A study led by researchers from the University of Arizona Cancer Center identified a biological mechanism that could lead to more effective treatments for breast cancer that has metastasized to the brain. By targeting the autophagy pathway, the researchers were able to disrupt breast cancer cells' ability to form brain metastases.

SourceUniversity of Arizona Health Sciences·JournalClinical and Translational Medicine·TypeRandomized controlled/clinical trial·DateJun 6, 2024

Diagnosis of lymphatic metastasis in breast cancer using nanoparticle technology - diagnosis, therapy, imaging, treatment

Researchers explore nanoparticle-based therapies to specifically target lymphatic metastasis in breast cancer, providing a promising solution for patient treatment. Nanoparticles deliver drugs directly to tumors, targeting cancer cells to destroy them or slow their growth, while also enhancing the immune response.

SourceBentham Science Publishers·JournalThe Open Neuroimaging Journal·DateMay 27, 2024

ASCO: Combination therapy significantly improves outcomes for patients with metastatic colorectal cancer

A study by UCLA Health Jonsson Comprehensive Cancer Center researchers found that combining experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer. The median progression-free survival was 6.2 months compared to 2.1 months f...

ASTRO clinical guideline on radiation therapy for bone metastases emphasizes patient-centered care

The updated clinical guideline recommends multiple dose-fractionation schemes to relieve pain and symptoms of bone and spine lesions. Advanced radiation techniques like intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT) are now routine clinical care for many patients.

SourceAmerican Society for Radiation Oncology·JournalPractical Radiation Oncology·DateMay 23, 2024

A biologic drug-device combination immunotherapy shows promise for patients with metastatic prostate cancer

A biologic drug-device combination therapy has shown promising results in treating metastatic prostate cancer, with 60% of patients experiencing an objective response. The treatment, SYNC-T, uses a cold-temperature probe to kill tumor cells and release immune-stimulating neoantigens, leading to a high response rate without severe toxic...